Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Approved to Start China Trial of Complement Factor Inhibitor

publication date: Feb 10, 2021

I-Mab of Shanghai was approved to start a China Phase I trial of TJ210/MOR210 as a monotherapy to treat advanced solid tumors. In 2018, I-Mab in-licensed greater China rights to the mAb from Germany's MorphoSys in a $105 million agreement. J210/MOR210 targets the complement factor C5a receptor 1 (C5aR1). Blocking C5aR1 is expected to improve the immune response by recruiting myeloid-derived suppressor cells, M2 macrophages and neutrophils. More details....

Stock Symbols: (NSDQ: IMAB) (FSE: MOR; NSDQ: MOR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.